Effects of the transobturator tape procedure on overactive bladder symptoms and quality of life: a prospective study.
Adult
Aged
Analysis of Variance
Female
Follow-Up Studies
Humans
Middle Aged
Patient Reported Outcome Measures
Patient Satisfaction
Postoperative Period
Preoperative Period
Prospective Studies
Quality of Life
Statistics, Nonparametric
Suburethral Slings
Surveys and Questionnaires
Time Factors
Treatment Outcome
Urinary Bladder, Overactive
/ physiopathology
Urinary Incontinence, Stress
/ physiopathology
Urinary Incontinence, Urge
/ physiopathology
Young Adult
Quality of Life
Suburethral Slings
Urinary Bladder, Overactive
Journal
International braz j urol : official journal of the Brazilian Society of Urology
ISSN: 1677-6119
Titre abrégé: Int Braz J Urol
Pays: Brazil
ID NLM: 101158091
Informations de publication
Date de publication:
Historique:
received:
02
03
2019
accepted:
19
05
2019
entrez:
7
12
2019
pubmed:
7
12
2019
medline:
23
1
2020
Statut:
ppublish
Résumé
This study aimed to evaluate the effects of transobturator tape (TOT) on overactive bladder (OAB) symptoms and quality of life. Patients with stress-predominant mixed urinary incontinence (MUI) who had undergone TOT procedures were considered candidates for this research. Preoperative assessment included anamnesis, pelvic examination, cough stress test (CST), and validated symptom severity and quality of life (QoL) questionnaires. The primary outcome, improvement and cure rates of OAB symptoms were determined based on the patient's baseline scores in symptom-related questions in OAB-V8. Secondary outcomes included the success rates of SUI, changes in the QoL score and patient satisfaction rates. A total of 104 patients were included in the study. Sixty-two patients underwent TOT placement alone, and 42 patients underwent TOT placement along with prolapse surgery. The mean follow-up period of the patients was 30.47 months range: 13-52 months. At the fi rst-year follow-up, 52 patients (50.0%) and 59 patients (56.7%) reported cure in preoperative urgency and urgency incontinence, respectively. The objective and subjective cure rates were 96.2% and 56.7%, respectively. A total of 80.7% of the cases had a 15-point improvement in QoL scores. MUS is not only a gold standard treatment in SUI but also presents as a promising treatment modality in stress-dominant MUI. Although the improvement rates of OAB symptoms signifi cantly decrease over time, QoL and patient satisfaction rates remain higher than any other treatment in this patient group at the third-year follow-up.
Identifiants
pubmed: 31808407
doi: 10.1590/S1677-5538.IBJU.2019.0158
pii: IBJU20190158
pmc: PMC6909856
doi:
Types de publication
Evaluation Study
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1186-1195Informations de copyright
Copyright® by the International Brazilian Journal of Urology.
Déclaration de conflit d'intérêts
None declared.
Références
Minerva Urol Nefrol. 2016 Oct;68(5):444-50
pubmed: 25585098
J Urol. 2009 Aug;182(2):596-600
pubmed: 19535107
Int Urogynecol J Pelvic Floor Dysfunct. 2008 Jun;19(6):857-61
pubmed: 18188489
Obstet Gynecol. 2008 Mar;111(3):611-21
pubmed: 18310363
Neurourol Urodyn. 2011 Jan;30(1):87-92
pubmed: 20860018
Geburtshilfe Frauenheilkd. 2014 Jan;74(1):63-68
pubmed: 24741120
Prog Urol. 2001 Dec;11(6):1306-13
pubmed: 11859672
BJU Int. 2000 May;85 Suppl 3:53-4; discussion 55-6
pubmed: 11954199
Neurourol Urodyn. 2017 Apr;36(4):902-908
pubmed: 28028822
Eur J Obstet Gynecol Reprod Biol. 2018 Feb;221:64-69
pubmed: 29248808
Female Pelvic Med Reconstr Surg. 2015 Sep-Oct;21(5):283-6
pubmed: 25900059
Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5
pubmed: 17049716
Eur Urol. 2007 Nov;52(5):1481-90
pubmed: 17482343
Int Urogynecol J Pelvic Floor Dysfunct. 2008 Oct;19(10):1359-62
pubmed: 18491026
Scand J Urol Nephrol. 1995 Mar;29(1):75-82
pubmed: 7618052
World J Urol. 2016 Apr;34(4):585-93
pubmed: 26231286
BJU Int. 2011 Mar;107(5):702-713
pubmed: 21355977
Int Urogynecol J. 2013 Mar;24(3):393-9
pubmed: 22777582
Int J Gynaecol Obstet. 2004 Jul;86 Suppl 1:S6-16
pubmed: 15302563
Int Urogynecol J. 2011 Aug;22(8):923-32
pubmed: 21455757
Int Urogynecol J Pelvic Floor Dysfunct. 2007 May;18(5):543-9
pubmed: 17036169
Eur Urol. 2010 Oct;58(4):532-43
pubmed: 20573443
Int Urogynecol J Pelvic Floor Dysfunct. 2007 Nov;18(11):1257-61
pubmed: 17345002
Int Urogynecol J Pelvic Floor Dysfunct. 2008 Aug;19(8):1049-54
pubmed: 18373046
Int Urogynecol J. 2014 Oct;25(10):1321-6
pubmed: 24562789
Neurourol Urodyn. 2010;29(1):213-40
pubmed: 20025020
J Am Geriatr Soc. 2001 Jul;49(7):892-9
pubmed: 11527480
Can Urol Assoc J. 2012 Oct;6(5 Suppl 2):S138-40
pubmed: 23092779
J Urol. 2014 Jan;191(1):114-9
pubmed: 23892190